With an unprecedented amount of life science investment being put to work, the industry faces a well known shortage of experienced Chief Medical Officers (CMO). Therefore, following an engagement involving defining clinical strategy for an innovative biopharma company, an experienced Alacrita Partner was deployed as Interim CMO at an innovative biopharma client for over two years.
Key activities included:Key activities included:
- Continued development of the lead candidate drug and other therapies in the company’s portfolio
- Medical support for the associated regulatory filings
- Representation of the company to investors and other external parties